Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03651128 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: bb2121
DRUG: Daratumumab
DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: Bortezomib
DRUG: Ixazomib
DRUG: Lenalidomide
DRUG: Carfilzomib
DRUG: Elotuzumab

Sponsor

Celgene